bpc 157 for immune system BPC-157 – Research Peptide BPC-157 - LeadWest Medical
Description
Emrosi demonstrated statistically significant superiority over the current standard-of-care treatment (Oracea 40-mg capsules) and placebo for Investigators Global Assessment treatment success and reduction in total inflammatory lesion count in both trials, Journey Medical reported
Nat Rev Gastroenterol Hepatol
CagriSema is filed for approval and represents Novo Nordisk's competitive response
A Turning Point, But Not a Final Decision Despite the momentum suggested by this update, important limitations remain
